ArticleWorld journal of gastroenterology2008
Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.
Article in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02874495 (Anticipation Effect on Painful Phenomenons Linked to Rectal Distension for Patients With a Crohn's Disease in Remission), which is not on this map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anticipation Effect on Painful Phenomenons Linked to Rectal Distension for Patients With a Crohn's Disease in Remission: Functional MRI Study
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review.Canadian journal of gastroenterology & hepatology · 2015Pooled it
- Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.BMJ (Clinical research ed.) · 2010Pooled it
- High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.Journal of pediatric gastroenterology and nutrition · 2014Trial
- Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.Cancer immunity · 2010Trial
- Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis.World journal of gastroenterology · 2010Trial
- Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease.BMC gastroenterology · 2026Article
- Tissue Eosinophilia of the Colonic Mucosa as a Potential Early Predictor of Failure to Achieve Clinical Remission in Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2026Article
- The Roles of Four Neutrophil-Derived Proteins as Non-Invasive Biomarkers in the Assessment of Inflammatory Bowel Disease.Journal of inflammation research · 2026Review
- Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Smart Capsule for Targeted Detection of Inflammation Levels Inside the GI Tract.IEEE transactions on bio-medical engineering · 2024Article
- Cirsimaritin Alleviates Dextran Sodium Sulfate-Induced Acute Colitis in Experimental Animals: A Therapeutic Approach for Inflammatory Bowel Disease.Preventive nutrition and food science · 2024Article
- Preventive Anti-inflammatory Effects of Apocynin on Acetic Acid-Induced Colitis in Rats.Inflammation · 2024Article
- Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2022Article
- Mapping of etiologies of computed tomography-proven acute colitis: a prospective cohort study.Scientific reports · 2022Article
- Amelioration of dextran sulfate sodium-induced colitis by autoinducer-2-deficientFrontiers in microbiology · 2022Article
- Article
- Article
- Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis.Frontiers in medicine · 2021Article
- Interdependence between Chromogranin-A, Alternatively Activated Macrophages, Tight Junction Proteins and the Epithelial Functions. A Human and In-Vivo/In-Vitro Descriptive Study.International journal of molecular sciences · 2020Article
- Nutritional status, environmental enteric dysfunction, and prevalence of rotavirus diarrhoea among children in Zambia.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate fecal calprotectin (FC) as a surrogate marker of treatment outcome of relapse of inflammatory bowel disease (IBD) and, to compare FC with fecal myeloperoxidase (MPO) and fecal eosinophil protein X (EPX).
methodsThirty eight patients with IBD, comprising of 27 with ulcerative colitis (UC) and 11 with Crohn's disease (CD) were investigated before treatment (inclusion), and after 4 and 8 wk of treatment. Treatment outcomes were evaluated by clinical features of disease activity and endoscopy in UC patients, and disease activity in CD patients. In addition, fecal samples were analyzed for FC by enzyme-linked immunosorbent assay (ELISA), and for MPO and EPX with radioimmunoassay (RIA).
resultsAt inclusion 37 of 38 (97%) patients had elevated FC levels (> 94.7 microg/g). At the end of the study, 31 of 38 (82%) patients fulfilled predefined criteria of a complete response [UC 21/27 (78%); CD 10/11 (91%)]. Overall, a normalised FC level at the end of the study predicted a complete response in 100% patients, whereas elevated FC level predicted incomplete response in 30%. Normalised MPO or EPX levels predicted a complete response in 100% and 90% of the patients, respectively. However, elevated MPO or EPX levels predicted incomplete response in 23% and 22%, respectively.
conclusionA normalised FC level has the potential to be used as a surrogate marker for successful treatment outcome in IBD patients. However, patients with persistent elevation of FC levels need further evaluation. FC and MPO provide superior discrimination than EPX in IBD treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.